MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 206065 | Name: Ravoxertinib
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ravoxertinib also known as GDC-0994, GDC994 and RG7842, is an orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.

Chemical Structure

Ravoxertinib
Ravoxertinib
CAS#1453848-26-4 (free base)

Theoretical Analysis

MedKoo Cat#: 206065

Name: Ravoxertinib

CAS#: 1453848-26-4 (free base)

Chemical Formula: C21H18ClFN6O2

Exact Mass: 440.1164

Molecular Weight: 440.86

Elemental Analysis: C, 57.21; H, 4.12; Cl, 8.04; F, 4.31; N, 19.06; O, 7.26

Price and Availability

Size Price Availability Quantity
5mg USD 90.00 Ready to ship
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 400.00 Ready to ship
100mg USD 650.00 Ready to ship
200mg USD 1,150.00 Ready to ship
500mg USD 2,750.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1453848-26-4 (free base) 1817728-45-2 (besylate) 1817728-47-4 (tosylate) 2070009-58-2 (HCl)
Synonym
GDC0994; GDC 0994; GDC-0994; RG7842; RG-7842; RG 7842; GDC994; GDC 994; GDC-994; Ravoxertinib
IUPAC/Chemical Name
(S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one
InChi Key
RZUOCXOYPYGSKL-GOSISDBHSA-N
InChi Code
InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1
SMILES Code
O=C1C=C(C2=NC(NC3=CC=NN3C)=NC=C2)C=CN1[C@@H](C4=CC=C(Cl)C(F)=C4)CO
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        
Biological target:
Ravoxertinib is an orally active ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively. It inhibits ERK-dependent p90RSK serine 380 phosphorylation in PMA-stimulated HepG2 cells with an IC50 value of 12 nM.
In vitro activity:
This article describes the discovery and characterization of ravoxertinib. Reference: J Med Chem. 2016 Jun 23;59(12):5650-60. https://pubmed.ncbi.nlm.nih.gov/27227380/
In vivo activity:
Ravoxertinib (RAH) treatment attenuates neurobehavioral deficits, the blood-brain barrier damage, and cerebral edema after subarachnoid hemorrhage (SAH). RAH treatment decreases the SAH-elevated apoptosis-related factor active caspase-3 and RIPK1 expression. RAH attenuated neuronal apoptosis in the basal cortex at 72 h after SAH in rats. These results suggest that RAH improves long-term neurologic deficits through early inhibition of Erk1/2 in experimental SAH. Reference: ACS Omega. 2023 May 23;8(22):19692-19704. https://pubmed.ncbi.nlm.nih.gov/37305289/
Solvent mg/mL mM
Solubility
DMSO 30.0 68.45
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 440.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Blake JF, Burkard M, Chan J, Chen H, Chou KJ, Diaz D, Dudley DA, Gaudino JJ, Gould SE, Grina J, Hunsaker T, Liu L, Martinson M, Moreno D, Mueller L, Orr C, Pacheco P, Qin A, Rasor K, Ren L, Robarge K, Shahidi-Latham S, Stults J, Sullivan F, Wang W, Yin J, Zhou A, Belvin M, Merchant M, Moffat J, Schwarz JB. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development. J Med Chem. 2016 Jun 23;59(12):5650-60. doi: 10.1021/acs.jmedchem.6b00389. Epub 2016 Jun 7. PMID: 27227380. 2. Yang MF, Sun SY, Lv HG, Wang WQ, Li HX, Sun JY, Zhang ZY. Ravoxertinib Improves Long-Term Neurologic Deficits after Experimental Subarachnoid Hemorrhage through Early Inhibition of Erk1/2. ACS Omega. 2023 May 23;8(22):19692-19704. doi: 10.1021/acsomega.3c01296. PMID: 37305289; PMCID: PMC10249378. 3. Janardhan HP, Dresser K, Hutchinson L, Trivedi CM. Pathological MAPK activation-mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib. JCI Insight. 2022 Sep 8;7(17):e153033. doi: 10.1172/jci.insight.153033. PMID: 36073544; PMCID: PMC9536262.
In vitro protocol:
1. Blake JF, Burkard M, Chan J, Chen H, Chou KJ, Diaz D, Dudley DA, Gaudino JJ, Gould SE, Grina J, Hunsaker T, Liu L, Martinson M, Moreno D, Mueller L, Orr C, Pacheco P, Qin A, Rasor K, Ren L, Robarge K, Shahidi-Latham S, Stults J, Sullivan F, Wang W, Yin J, Zhou A, Belvin M, Merchant M, Moffat J, Schwarz JB. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development. J Med Chem. 2016 Jun 23;59(12):5650-60. doi: 10.1021/acs.jmedchem.6b00389. Epub 2016 Jun 7. PMID: 27227380.
In vivo protocol:
1. Yang MF, Sun SY, Lv HG, Wang WQ, Li HX, Sun JY, Zhang ZY. Ravoxertinib Improves Long-Term Neurologic Deficits after Experimental Subarachnoid Hemorrhage through Early Inhibition of Erk1/2. ACS Omega. 2023 May 23;8(22):19692-19704. doi: 10.1021/acsomega.3c01296. PMID: 37305289; PMCID: PMC10249378. 2. Janardhan HP, Dresser K, Hutchinson L, Trivedi CM. Pathological MAPK activation-mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib. JCI Insight. 2022 Sep 8;7(17):e153033. doi: 10.1172/jci.insight.153033. PMID: 36073544; PMCID: PMC9536262.
1: Yang MF, Sun SY, Lv HG, Wang WQ, Li HX, Sun JY, Zhang ZY. Retraction of "Ravoxertinib Improves Long-Term Neurologic Deficits after Experimental Subarachnoid Hemorrhage through Early Inhibition of Erk1/2". ACS Omega. 2024 Jun 4;9(24):26736. doi: 10.1021/acsomega.4c03199. PMID: 38911811; PMCID: PMC11190904. 2: Chen Y, Sang Y, Li S, Xue J, Chen M, Hong S, Lv W, Sehgal K, Xiao H, Liu R. The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells. Transl Oncol. 2024 Jul;45:101991. doi: 10.1016/j.tranon.2024.101991. Epub 2024 May 9. PMID: 38728872; PMCID: PMC11107342. 3: Yang MF, Sun SY, Lv HG, Wang WQ, Li HX, Sun JY, Zhang ZY. Ravoxertinib Improves Long-Term Neurologic Deficits after Experimental Subarachnoid Hemorrhage through Early Inhibition of Erk1/2. ACS Omega. 2023 May 23;8(22):19692-19704. doi: 10.1021/acsomega.3c01296. Retraction in: ACS Omega. 2024 Jun 04;9(24):26736. doi: 10.1021/acsomega.4c03199. PMID: 37305289; PMCID: PMC10249378. 4: Savic D, Steinbichler TB, Ingruber J, Negro G, Aschenbrenner B, Riechelmann H, Ganswindt U, Skvortsov S, Dudás J, Skvortsova II. Erk1/2-Dependent HNSCC Cell Susceptibility to Erastin-Induced Ferroptosis. Cells. 2023 Jan 16;12(2):336. doi: 10.3390/cells12020336. PMID: 36672272; PMCID: PMC9856753. 5: Jiang F, Liu G, Chen X, Li Q, Fang F, Shen X. Hsa_circ_0044301 Regulates Gastric Cancer Cell's Proliferation, Migration, and Invasion by Modulating the Hsa-miR-188-5p/DAXX Axis and MAPK Pathway. Cancers (Basel). 2022 Aug 29;14(17):4183. doi: 10.3390/cancers14174183. PMID: 36077718; PMCID: PMC9454757. 6: Janardhan HP, Dresser K, Hutchinson L, Trivedi CM. Pathological MAPK activation-mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib. JCI Insight. 2022 Sep 8;7(17):e153033. doi: 10.1172/jci.insight.153033. PMID: 36073544; PMCID: PMC9536262. 7: Lebedev TD, Khabusheva ER, Mareeva SR, Ivanenko KA, Morozov AV, Spirin PV, Rubtsov PM, Snezhkina AV, Kudryavtseva AV, Sorokin MI, Buzdin AA, Prassolov VS. Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. J Biol Chem. 2022 Aug;298(8):102226. doi: 10.1016/j.jbc.2022.102226. Epub 2022 Jul 1. PMID: 35787369; PMCID: PMC9358475. 8: Jin Q, Yang H, Jing Z, Hong-Hua W, Ben-Jing S, Li-Ting W, Li-Juan Y, Wei X, Xia K, Juan W, Wei Z. IL4/IL4R signaling promotes the osteolysis in metastatic bone of CRC through regulating the proliferation of osteoclast precursors. Mol Med. 2021 Dec 4;27(1):152. doi: 10.1186/s10020-021-00411-2. PMID: 34863091; PMCID: PMC8642926. 9: Takahashi RH, Grandner JM, Bobba S, Liu Y, Beroza P, Zhang D, Ma S. Novel Homodimer Metabolites of GDC-0994 via Cytochrome P450-Catalyzed Radical Coupling. Drug Metab Dispos. 2020 Jun;48(6):521-527. doi: 10.1124/dmd.119.090019. Epub 2020 Mar 31. PMID: 32234735. 10: Varga A, Soria JC, Hollebecque A, LoRusso P, Bendell J, Huang SA, Wagle MC, Okrah K, Liu L, Murray E, Sanabria-Bohorquez SM, Tagen M, Dokainish H, Mueller L, Burris H. A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 Mar 15;26(6):1229-1236. doi: 10.1158/1078-0432.CCR-19-2574. Epub 2019 Dec 17. PMID: 31848189. 11: Roskoski R Jr. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacol Res. 2019 Apr;142:151-168. doi: 10.1016/j.phrs.2019.01.039. Epub 2019 Feb 20. Erratum in: Pharmacol Res. 2019 May;143:206. doi: 10.1016/j.phrs.2019.03.019. PMID: 30794926. 12: Blake JF, Burkard M, Chan J, Chen H, Chou KJ, Diaz D, Dudley DA, Gaudino JJ, Gould SE, Grina J, Hunsaker T, Liu L, Martinson M, Moreno D, Mueller L, Orr C, Pacheco P, Qin A, Rasor K, Ren L, Robarge K, Shahidi-Latham S, Stults J, Sullivan F, Wang W, Yin J, Zhou A, Belvin M, Merchant M, Moffat J, Schwarz JB. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl- 1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development. J Med Chem. 2016 Jun 23;59(12):5650-60. doi: 10.1021/acs.jmedchem.6b00389. Epub 2016 Jun 7. PMID: 27227380.

View History

Tucatinib

Tucatinib

New Featured